APA

Josting A., Reiser M., Wickramanayake P. D., Rueffer U., Draube A., Söhngen D., Tesch H., Wolf J., Diehl V. & Engert A. (20000518). Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma. : Leukemia & lymphoma.

Chicago

Josting A, Reiser M, Wickramanayake P D, Rueffer U, Draube A, Söhngen D, Tesch H, Wolf J, Diehl V and Engert A. 20000518. Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma. : Leukemia & lymphoma.

Harvard

Josting A., Reiser M., Wickramanayake P. D., Rueffer U., Draube A., Söhngen D., Tesch H., Wolf J., Diehl V. and Engert A. (20000518). Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma. : Leukemia & lymphoma.

MLA

Josting A, Reiser M, Wickramanayake P D, Rueffer U, Draube A, Söhngen D, Tesch H, Wolf J, Diehl V and Engert A. Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma. : Leukemia & lymphoma. 20000518.